(Q36780744)

16 August 2017

1 reference

title

From bench to bedside--experimental rationale for immune-specific therapies in the inflamed peripheral nerve (English)

1 reference

16 August 2017

2

Hans-Peter Hartung

1 reference

16 August 2017

3

Bernd C Kieseier

1 reference

16 August 2017

1

Gerd Meyer zu Hörste

1 reference

16 August 2017

publication date

1 April 2007

1 reference

Nature Clinical Practice Neurology

16 August 2017

published in

1 reference

16 August 2017

volume

3

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

198-211

1 reference

Kinetics of anti-peripheral nerve myelin antibody in patients with Guillain-Barré syndrome treated and not treated with plasmapheresis

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

T cell activation in Guillain-Barré syndrome and in MS: elevated serum levels of soluble IL-2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

Cyclo-oxygenases and prostaglandins in acute inflammatory demyelination of the peripheral nerve

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

21 January 2018

Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Animal models of immune-mediated neuropathies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Experimental allergic neuritis in the SJL/J mouse: induction of severe and reproducible disease with bovine peripheral nerve myelin and pertussis toxin with or without interleukin-12

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

BALB/c mice have more CD4+CD25+ T regulatory cells and show greater susceptibility to suppression of their CD4+CD25- responder T cells than C57BL/6 mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Imbalance of regulatory T cells in human autoimmune diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

P0 protein peptide 180-199 together with pertussis toxin induces experimental autoimmune neuritis in resistant C57BL/6 mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

P0(106-125) is a neuritogenic epitope of the peripheral myelin protein P0 and induces autoimmune neuritis in C57BL/6 mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Guillain-Barré syndrome in northern China Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Peripheral neuropathies and anti-glycolipid antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Biphasic form of experimental autoimmune neuritis in dark Agouti rats and its oral therapy by antigen-specific tolerization

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Chronic experimental allergic neuritis. An electrophysiological and histological study in the rabbit

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Carbohydrate mimicry: a new paradigm of autoimmune diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

The immunobiology of Guillain-Barré syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Accumulation of immunoglobulin across the 'blood-nerve barrier' in spinal roots in adoptive transfer experimental autoimmune neuritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Sera from Guillain-Barré patients enhance leakage in blood-nerve barrier model

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Effects on axonal conduction of anti-ganglioside sera and sera from patients with Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Guillain-Barré syndrome: activated complement components C3a and C5a in CSF

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Presence of the terminal complement complex (C5b-9) precedes myelin degradation in immune-mediated demyelination of the rat peripheral nervous system

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Adoptive transfer of experimental allergic neuritis in the immune suppressed host

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

How T cells 'see' antigen

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Recognition of lipid antigens by T cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Increased circulating T cell reactivity to GM1 ganglioside in patients with Guillain-Barré syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain–Barré syndrome and experimental allergic neuritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Enhanced B7 costimulatory molecule expression in inflammatory human sural nerve biopsies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Lymphocyte homing and homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

The role of the very late antigen-4 and its counterligand vascular cell adhesion molecule-1 in the pathogenesis of experimental autoimmune neuritis of the Lewis rat.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Role of the leukocyte-adhesion molecule L-selectin in experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Role of integrins in the peripheral nervous system

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Matrix metalloproteinase expression during experimental autoimmune neuritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Immune attack on the schwann cell surface in acute inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Pathology of the motor-sensory axonal Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Human peripheral nerve macrophages in normal and pathological conditions

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Sequential expression of transforming growth factor-beta1 by T-cells, macrophages, and microglia in rat spinal cord during autoimmune inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barré syndrome: decreased concentrations in the early course and increase with motor function

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Peripheral deletion of antigen-reactive T cells in oral tolerance.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Acute axonal Guillain‐Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Treatment of dys-immune neuropathies.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

The treatment of experimental allergic neuritis by plasma exchange

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

IgG immunoadsorption in experimental allergic neuritis: effect on antibody levels and clinical course

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Human immunoglobulin ameliorates rat experimental autoimmune neuritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Fc portion of intravenous immunoglobulin suppresses the induction of experimental allergic neuritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Suppression of experimental autoimmune neuritis by leflunomide

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Chronic inflammatory demyelinating polyneuropathy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Nerve lesions induced by macrophage activation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Suppression of autoimmune neuritis in IFN-gamma receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor-alpha processing attenuates experimental autoimmune neuritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

The role of macrophages in immune-mediated damage to the peripheral nervous system

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Multifocal motor neuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Treatment of peripheral nerve disorders

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-alpha 2a

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Treatment of Guillain-Barré syndrome with interferon-beta

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Multifocal motor neuropathy during treatment with infliximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Cyclosporine in chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

High-dose rituximab and anti-MAG-associated polyneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti-SGPG IgM antibody

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Worsening after rituximab treatment in anti-mag neuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

B cells move to centre stage: novel opportunities for autoimmune disease treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H).

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Sensorimotor neuropathy resembling CIDP in patients receiving FK506.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Nasal administration of recombinant rat IL-4 ameliorates ongoing experimental autoimmune neuritis and inhibits demyelination

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

The action mechanism of cyclooxygenase-2 inhibitor for treatment of experimental allergic neuritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Protective effect of Rolipram in experimental autoimmune neuritis: protection is associated with down-regulation of IFN-gamma and inflammatory chemokines as well as up-regulation of IL-4 in peripheral nervous system

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Induction of experimental autoimmune neuritis with peripheral myelin protein-22.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Effects of cyclosporin A treatment on clinical course and inflammatory cell apoptosis in experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Experimental allergic neuritis. I. Rat strain differences in the response to bovine myelin antigens

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Chronic relapsing experimental allergic neuritis induced by repeated transfer of P2-protein reactive T cell lines

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Experimental allergic neuritis induced in SJL mice by bovine P2.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Experimental autoimmune peripheral neuritis induced in BALB/c mice by myelin basic protein-specific T cell clones

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

The neuritogenicity and encephalitogenicity of P2 in the rat, guinea-pig and rabbit

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Relation of clinical, serological, morphological, and electrophysiological findings in galactocerebroside-induced experimental allergic neuritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Experimental sensory neuropathy induced by sensitization with ganglioside GD1b

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Attempts to induce chronic experimental allergic neuritis in strain 13 and Hartley guinea pigs

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Induction of allergic neuritis in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Appropriate number of plasma exchanges in Guillain-Barré syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Intravenous immunoglobulin versus plasma exchange in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

IVIg treatment improves multifocal motor neuropathy: easy to start but difficult to stop

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Improvement following interferon-alpha 2A in chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Successful treatment of Guillain-Barré syndrome with combined administration of interferon-beta-1a and intravenous immunoglobulin.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Chronic motor neuropathies: response to interferon-beta1a after failure of conventional therapies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Mycophenolate in treatment-resistant inflammatory neuropathies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0452

7 January 2021

Identifiers

DOI

10.1038/NCPNEURO0452

1 reference

Dimensions Publication ID

16 August 2017

1002926579

0 references

1 reference